IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction.

The mechanism of airway eosinophilia during antigen-induced inflammation was investigated by measurement of eosinophil-active cytokines utilizing an eosinophil survival assay. In the first study, 4 patients with allergic rhinitis underwent segmental bronchoprovocation (SBP) with low, medium, and high doses of ragweed extract instilled into different bronchial subsegments; bronchoalveolar lavage (BAL) fluids were collected from each segment 12 min and 48 h after challenge. Eosinophil granule proteins and eosinophil survival activity were significantly elevated in the 48-h (late-phase) BAL fluids from these segments. Correlations were observed between the concentrations of eosinophil granule proteins and eosinophil survival activity (rs = 0.717 to 0.880, p < 0.001) in BAL fluids. Eosinophil survival activity was completely neutralized by anti-IL-5 monoclonal antibody in five of the seven 48-h samples tested representing three of the 4 patients. In the two remaining samples, eosinophil survival activity was only partially neutralized by either anti-IL-5 antibody or anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) but was completely neutralized by anti-IL-5 and anti-GM-CSF in combination. Subsequently, in the second study, 10 patients with allergic rhinitis were challenged by SBP with ragweed extract. Eosinophil survival activity was significantly elevated in the 48-h BAL fluids; this activity was partially neutralized by anti-IL-5 antibody about (48%) and completely neutralized by the combination of anti-IL-5 and anti-GM-CSF antibodies. These findings suggest that the eosinophil survival activity in the late inflammatory lesions following SBP with allergen is mainly associated with IL-5, with small contributions from GM-CSF.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  J. Abrams,et al.  Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples , 1992, Immunological reviews.

[2]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[3]  A. Capron,et al.  Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease , 1992, The Journal of experimental medicine.

[4]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[5]  H. Kita,et al.  Glucocorticoids inhibit cytokine-mediated eosinophil survival. , 1991, Journal of immunology.

[6]  R. L. Barker,et al.  Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity. Evidence of a functional role for ProMBP. , 1991, The Journal of clinical investigation.

[7]  H. Kita,et al.  Materials and Methods Brief Definitive Report Granulocyte/macrophage Colony-stimulating Factor and Interleukin 3 Release from Human Peripheral Blood Eosinophils and Neutrophils , 2022 .

[8]  M. Mezzetti,et al.  Interleukin-1 binds to specific receptors on human bronchial epithelial cells and upregulates granulocyte/macrophage colony-stimulating factor synthesis and release. , 1991, American journal of respiratory cell and molecular biology.

[9]  G. Gleich,et al.  Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. , 1991, The Journal of clinical investigation.

[10]  S. Durham,et al.  Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects , 1991, The Journal of experimental medicine.

[11]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[12]  J. Kalden,et al.  Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. , 1990, Journal of immunology.

[13]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[14]  G. Gleich.  The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[15]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[16]  W. Paul,et al.  Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores , 1989, Nature.

[17]  Ji Ming Wang,et al.  Recombinant human interleukin 5 is a selective eosinophil chemoattractant , 1989, European journal of immunology.

[18]  R. Kyle,et al.  IgA-induced eosinophil degranulation. , 1989, Journal of immunology.

[19]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[20]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.

[21]  Y. Sonoda,et al.  Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5. , 1989, Leukemia.

[22]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[23]  A. Donnenberg,et al.  Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[25]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[26]  M. F. Shannon,et al.  Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Dipersio,et al.  Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. , 1986, Journal of immunology.

[28]  C. Begley,et al.  Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. , 1986, Blood.

[29]  G. Gleich,et al.  The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.

[30]  S. Durham,et al.  Eosinophils, bronchial hyperreactivity and late‐phase asthmatic reactions , 1985, Clinical allergy.

[31]  G. Gleich,et al.  The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? , 1982, The Journal of allergy and clinical immunology.

[32]  K. E. Holley,et al.  IDENTIFICATION BY IMMUNOFLUORESCENCE OF EOSINOPHIL GRANULE MAJOR BASIC PROTEIN IN LUNG TISSUES OF PATIENTS WITH BRONCHIAL ASTHMA , 1982, The Lancet.

[33]  N. Thomson,et al.  Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. , 1981, The Journal of allergy and clinical immunology.

[34]  G. R. Pullen,et al.  Criteria of cell killing in vitro. , 1981, Journal of immunological methods.

[35]  B. Rotman,et al.  Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. , 1966, Proceedings of the National Academy of Sciences of the United States of America.